Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 8/20 | 0.39 |
| ▸ | GRM5 | P41594 | 7/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23210751 | 0.96 | GRM5 (0.40) | GRM1GRM5WNT3ASCN9APDK4 | |
| SCHEMBL30308834 | 0.96 | GRM5 (0.40) | GRM1GRM5WNT3ASCN9APDK4 | |
| SCHEMBL29907118 | 0.96 | GRM5 (0.40) | GRM1GRM5WNT3ASCN9APDK4 | |
| SCHEMBL29907175 | 0.79 | WNT3A (0.41) | GRM1GRM5WNT3ASCN9APDK4 | |
| SCHEMBL23210926 | 0.79 | WNT3A (0.41) | GRM1GRM5WNT3ASCN9APDK4 | |
| SCHEMBL23211098 | 0.76 | KDM1A (0.36) | GRM1GRM5WNT3APDK4TNK2 | |
| SCHEMBL29907117 | 0.76 | KDM1A (0.36) | GRM1GRM5WNT3APDK4TNK2 | |
| SCHEMBL23211063 | 0.74 | WNT3A (0.40) | GRM1GRM5WNT3APDK4TNK2 | |
| SCHEMBL29907086 | 0.74 | WNT3A (0.40) | GRM1GRM5WNT3APDK4TNK2 | |
| SCHEMBL23211129 | 0.73 | JAK2 (0.34) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4045151-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021076602-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | GRM1 2117/4885GRM5 1935/4885WNT3A 2837/4885 |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | GRM1 2117/4885GRM5 1935/4885WNT3A 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.